O1385

Ozagrel hydrochloride hydrate

≥98% (HPLC), solid

• Sinónimos: (E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
• Fórmula empírica (notación de Hill): C₁₃H₁₂N₂O₂ · HCl · xH₂O
• Número de CAS: 78712-43-3
• Peso molecular: 264.71 (anhydrous basis)
• Número MDL: MFCD00911569
• Código UNSPSC: 12352200
• ID de la sustancia en PubChem: 24897942
• NACRES: NA.77

Propiedades

• Ensayo: ≥98% (HPLC)
• Formulario: solid
• condiciones de almacenamiento: desiccated
• color: white to off-white
• solubilidad: H₂O: soluble
• temp. de almacenamiento: room temp
• cadena SMILES: O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
• InChI: 1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
• Clave InChI: OWIZTYOMGVTSDP-TXOOBNKBSA-N

Descripción

Aplicación

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:

• in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction[1]
• to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes[2]
• to test its effect on arteriolar vasoconstriction in hyperglycemic mice[3]

Acciones bioquímicas o fisiológicas

Ozagrel is a selective thromboxane A₂ synthase (TXA₂) inhibitor.

Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation.[4] Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia.[4] It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).[5]

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 2
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable
• Equipo de protección personal: Eyeshields, Gloves, type N95 (US)